Molecular Mechanisms Mediating Ceftazidime/Avibactam Resistance Amongst Carbapenem-Resistant Klebsiella pneumoniae Isolates from Cancer Patients

References

• Lee Y, Bradley N. Overview and insights into carbapenem allergy. Pharmacy. 2019;7(3):110. doi:10.3390/pharmacy7030110
   Web of Science ®Google Scholar
• Elshamy AA, Aboshanab KM. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Future Sci OA. 2020;6(3):FSO438. doi:10.2144/fsoa-2019-0098
   Web of Science ®Google Scholar
• Wyres K, Holt K. Regional differences in carbapenem-resistant Klebsiella pneumoniae. Lancet Infect Dis. 2022;22(3):309–310. doi:10.1016/S1473-3099(21)00425-4
   Web of Science ®Google Scholar
• Zhang WX, Chen HY, Chen C, et al. Resistance phenotype and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae isolates in Shanghai. Microb Drug Resist. 2021;27(10):1312–1318. doi:10.1089/mdr.2020.0390
   PubMed Web of Science ®Google Scholar
• Codjoe FS, Donkor ES. Carbapenem resistance: a Review. Med Sci. 2017;6(1):1.
   Google Scholar
• Hammoudi Halat D, Ayoub Moubareck C. The current burden of carbapenemases: review of significant properties and dissemination among gram-negative bacteria. Antibiotics. 2020;9(4):186. doi:10.3390/antibiotics9040186
   Web of Science ®Google Scholar
• Mojica MF, Rossi MA, Vila AJ, Bonomo RA. The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 2022;22(1):e28–e34. doi:10.1016/S1473-3099(20)30868-9
   PubMed Web of Science ®Google Scholar
• Dabos L, Oueslati S, Bernabeu S, Bonnin RA, Dortet L, Naas T. To be or not to be an OXA-48 carbapenemase. Microorganisms. 2022;10(2):258. doi:10.3390/microorganisms10020258
   Web of Science ®Google Scholar
• Di Domenico EG, Cavallo I, Sivori F, et al. Biofilm production by carbapenem-resistant Klebsiella pneumoniae significantly increases the risk of death in oncological patients. Front Cell Infect Microbiol. 2020;10(10):561741. doi:10.3389/fcimb.2020.561741
   Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Criscuolo M, Trecarichi EM. Ceftazidime/avibactam and ceftolozane/tazobactam for multidrug-resistant gram negatives in patients with hematological malignancies: current experiences. Antibiotics. 2020;9(2):58. doi:10.3390/antibiotics9020058
   Web of Science ®Google Scholar
• Cavallini S, Unali I, Bertoncelli A, Cecchetto R, Mazzariol A. Ceftazidime/avibactam resistance is associated with different mechanisms in KPC-producing Klebsiella pneumoniae strains. Acta Microbiol Immunol Hung. 2021;2021:1626.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. Wayne, PA, USA: CLSI; 2020.
   Google Scholar
• Bina M, Pournajaf A, Mirkalantari S, Talebi M, Irajian G. Detection of the Klebsiella pneumoniae carbapenemase (KPC) in K. pneumoniae isolated from the clinical samples by the phenotypic and genotypic methods. Iran J Pathol. 2015;10(3):199–205.
   PubMedGoogle Scholar
• Monteiro J, Widen RH, Pignatari AC, Kubasek C, Silbert S. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother. 2012;67(4):906–909. doi:10.1093/jac/dkr563
   PubMed Web of Science ®Google Scholar
• Wassef M, Abdelhaleim M, AbdulRahman E, Ghaith D. The role of OmpK35, OmpK36 porins, and production of β-lactamases on imipenem susceptibility in Klebsiella pneumoniae clinical isolates, Cairo, Egypt. Microb Drug Resist. 2015;21(6):577–580. doi:10.1089/mdr.2014.0226
   Web of Science ®Google Scholar
• Metwally L, Gomaa N, Attallah M, Kamel N. High prevalence of Klebsiella pneumoniae carbapenemase–mediated resistance in K. pneumoniae isolates from Egypt. East Mediterr Health J. 2013;19(11):947–952. doi:10.26719/2013.19.11.947
   Web of Science ®Google Scholar
• Kotb S, Lyman M, Ismail G. Epidemiology of Carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare-associated Infections Surveillance Data, 2011-2017. Antimicrob Resist Infect Control. 2020;9(1):2. doi:10.1186/s13756-019-0639-7
   PubMed Web of Science ®Google Scholar
• Senchyna F, Gaur RL, Sandlund J, et al. Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016. Diagn Microbiol Infect Dis. 2019;93(3):250–257. doi:10.1016/j.diagmicrobio.2018.10.004
   Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18–27. doi:10.1016/j.jgar.2019.12.009
   PubMed Web of Science ®Google Scholar
• Li D, Liao W, Huang HH, et al. Emergence of hypervirulent ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital. Infect Drug Resist. 2020;3(13):2673–2680. doi:10.2147/IDR.S257477
   Web of Science ®Google Scholar
• Castón JJ, Gallo M, García M, et al. Ceftazidime–avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort. Int J Antimicrob Agents. 2020;56(3):106075. doi:10.1016/j.ijantimicag.2020.106075
   Web of Science ®Google Scholar
• Di Bella S, Giacobbe DR, Maraolo AE, et al. Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. J Glob Antimicrob Resist. 2021;25:268–281. doi:10.1016/j.jgar.2021.04.001
   PubMed Web of Science ®Google Scholar
• Castón JJ, Lacort-Peralta I, Martín-Dávila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase–producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118–123. doi:10.1016/j.ijid.2017.03.021
   PubMed Web of Science ®Google Scholar
• Metafuni E, Criscuolo M, Spanu T, Sica S. Ceftazidime–avibactam for gram–negative multidrug–resistant bacteria in hematological patients: a single–center experience. Ann Hematol. 2019;98(6):1495–1497. doi:10.1007/s00277-018-3535-y
   Web of Science ®Google Scholar
• Liu X, Chu Y, Yue H, Huang X, Zhou G. Risk factors for and clinical outcomes of ceftazidime–avibactam–resistant carbapenem–resistant Klebsiella pneumoniae nosocomial infections: a single–center retrospective study. Infection. 2022. doi:10.1007/s15010-022-01781-3
   Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime–avibactam treatment failures and resistance among patients with carbapenem–resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5):e02497–17. doi:10.1128/AAC.02497-17
   PubMed Web of Science ®Google Scholar
• Di Pietrantonio M, Brescini L, Candi J, et al. Ceftazidime–avibactam for the treatment of multidrug–resistant pathogens: a retrospective, single center study. Antibiotics. 2022;11(3):321. doi:10.3390/antibiotics11030321
   Web of Science ®Google Scholar
• Baidya S, Sharma S, Mishra SK, Kattel HP, Parajuli K, Sherchand JB. Biofilm formation by pathogens causing ventilator–associated pneumonia at intensive care units in a tertiary care hospital: an armor for refuge. Biomed Res Int. 2021;28(2021):8817700.
   Google Scholar
• Garg VK, Mishra S, Gupta N, et al. Microbial and antibiotic susceptibility profile among isolates of clinical samples of cancer patients admitted in the intensive care unit at regional tertiary care cancer center: a retrospective observational study. Indian J Crit Care Med. 2019;23(2):67–72. doi:10.5005/jp-journals-10071-23119
   Web of Science ®Google Scholar
• Li X, Ke H, Wu W, Tu Y, Zhou H, Yu Y. Molecular mechanisms driving the in vivo development of kpc-71-mediated resistance to ceftazidime-avibactam during treatment of carbapenem-resistant Klebsiella pneumoniae infections. mSphere. 2021;6(6):e0085921. doi:10.1128/mSphere.00859-21
   PubMed Web of Science ®Google Scholar
• Moemen D, Masallat DT. Prevalence and characterization of carbapenem–resistant Klebsiella pneumoniae isolated from intensive care units of Mansoura University hospitals. Egypt J Basic Appl Sci. 2017;4:37–41.
   Google Scholar
• Abdulall AK, Tawfick MM, El Manakhly AR, El Kholy A. Carbapenem-resistant Gram-negative bacteria associated with catheter-related bloodstream infections in three intensive care units in Egypt. Eur J Clin Microbiol Infect Dis. 2018;37(9):1647–1652. doi:10.1007/s10096-018-3294-7
   PubMed Web of Science ®Google Scholar
• Chatzidimitriou M, Chatzivasileiou P, Sakellariou G, et al. Ceftazidime/avibactam and eravacycline susceptibility of carbapenem-resistant Klebsiella pneumoniae in two Greek tertiary teaching hospitals. Acta Microbiol Immunol Hung. 2021;68(2):65–72. doi:10.1556/030.2021.01364
   Web of Science ®Google Scholar
• Ainoda Y, Aoki K, Ishii Y, et al. Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae ST258 isolated from a Japanese patient without a history of foreign travel - a new public health concern in Japan: a case report. BMC Infect Dis. 2019;19(1):20. doi:10.1186/s12879-018-3649-9
   Web of Science ®Google Scholar
• Alghoribi MF, Binkhamis K, Alswaji AA, et al. Genomic analysis of the first KPC-producing Klebsiella pneumoniae isolated from a patient in Riyadh: a new public health concern in Saudi Arabia. J Infect Public Health. 2020;13(4):647–650. doi:10.1016/j.jiph.2020.01.003
   Web of Science ®Google Scholar
• Fontana C, Favaro M, Campogiani L, et al. Ceftazidime/avibactam-resistant Klebsiella pneumoniae subsp. pneumoniae isolates in a tertiary Italian hospital: identification of a new mutation of the carbapenemase type 3 (KPC-3) gene conferring ceftazidime/avibactam resistance. Microorganisms. 2021;9(11):2356. doi:10.3390/microorganisms9112356
   Web of Science ®Google Scholar
• Liao Q, Deng J, Feng Y, et al. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections. J Infect Public Health. 2022;15(5):545–549. doi:10.1016/j.jiph.2022.04.002
   Web of Science ®Google Scholar
• Mataseje LF, Boyd DA, Fuller J, et al. Characterization of OXA-48-like carbapenemase producers in Canada, 2011-14. J Antimicrob Chemother. 2018;73(3):626–633. doi:10.1093/jac/dkx462
   Web of Science ®Google Scholar
• Bakthavatchalam YD, Routray A, Mane A, et al. In vitro activity of ceftazidime-avibactam and its comparators against carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019. Diagn Microbiol Infect Dis. 2022;103(1):115652. doi:10.1016/j.diagmicrobio.2022.115652
   PubMed Web of Science ®Google Scholar
• Zhang P, Shi Q, Hu H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 2020;26(1):124.e1–124.e4. doi:10.1016/j.cmi.2019.08.020
   PubMed Web of Science ®Google Scholar
• Yu W, Xiong L, Luo Q, et al. In vitro activity comparison of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections with carbapenem-resistant organisms in China. Front Cell Infect Microbiol. 2021;25(11):780365. doi:10.3389/fcimb.2021.780365
   Web of Science ®Google Scholar
• Cui X, Shan B, Zhang X, et al. Reduced ceftazidime-avibactam susceptibility in KPC-producing Klebsiella pneumoniae from patients without ceftazidime-avibactam use history - a multicenter study in China. Front Microbiol. 2020;23(11):1365. doi:10.3389/fmicb.2020.01365
   Web of Science ®Google Scholar
• Humphries RM, Hemarajata P. Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3. Antimicrob Agents Chemother. 2017;61(6):e00537–17. doi:10.1128/AAC.00537-17
   PubMed Web of Science ®Google Scholar
• Castanheira M, Doyle TB, Hubler C, Sader HS, Mendes RE. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. Int J Antimicrob Agents. 2020;56(1):106011. doi:10.1016/j.ijantimicag.2020.106011
   PubMed Web of Science ®Google Scholar
• Shen Z, Ding B, Ye M, et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2017;72(7):1930–1936.
   Web of Science ®Google Scholar